source
- Replimune's oncolytic virus therapy Tudriqev receives FDA accelerated approval for advanced melanomaThe U.S. Food and Drug Administration has granted approval to Replimune's melanoma treatment, ending a series of earlier rejections after an advisory panel advocated for the drug. The therapy, pre…
- Tarsus to acquire eye-drug startup Alkeus in up to $800 million dealTarsus Pharmaceuticals announced Thursday that it will buy Alkeus Pharmaceuticals for up to $800 million, consisting of $270 million in cash and $180 million in stock. The agreement also provides…